Immunoglobulin E Concentration, Serum (IGES)

Categories: Immune diseases

Aliases & Classifications for Immunoglobulin E Concentration, Serum

MalaCards integrated aliases for Immunoglobulin E Concentration, Serum:

Name: Immunoglobulin E Concentration, Serum 57 13 71
Allergy and Asthma Susceptibility 57
Iges 57


External Ids:

OMIM® 57 147061
UMLS 71 C1840252

Summaries for Immunoglobulin E Concentration, Serum

MalaCards based summary : Immunoglobulin E Concentration, Serum, also known as allergy and asthma susceptibility, is related to asthma and hypereosinophilic syndrome. An important gene associated with Immunoglobulin E Concentration, Serum is IGES (Immunoglobulin E Concentration, Serum). The drugs Ertapenem and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and lung.

More information from OMIM: 147061

Related Diseases for Immunoglobulin E Concentration, Serum

Diseases related to Immunoglobulin E Concentration, Serum via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 31)
# Related Disease Score Top Affiliating Genes
1 asthma 11.1
2 hypereosinophilic syndrome 11.1
3 allergic rhinitis 11.1
4 dermatitis 11.1
5 ige responsiveness, atopic 11.0
6 hyper ige syndrome 11.0
7 allergic bronchopulmonary aspergillosis 11.0
8 food allergy 11.0
9 milk allergy 11.0
10 vernal keratoconjunctivitis 11.0
11 dermatitis, atopic 10.9
12 lung abscess 10.8
13 beta-lactam allergy 10.8
14 protein-losing enteropathy 10.8
15 orbital cellulitis 10.8
16 neurogenic bladder 10.8
17 exocrine pancreatic insufficiency 10.8
18 opisthorchiasis 10.8
19 cellulitis 10.8
20 nut allergy 10.8
21 kimura disease 10.8
22 hepatitis a 10.0
23 rhinitis 10.0
24 esophagitis, eosinophilic, 1 9.9
25 drug allergy 9.9
26 tomato allergy 9.9
27 esophagitis 9.9
28 urticaria 9.9
29 exercise-induced anaphylaxis 9.9
30 dysphagia 9.9
31 seizure disorder 9.9

Graphical network of the top 20 diseases related to Immunoglobulin E Concentration, Serum:

Diseases related to Immunoglobulin E Concentration, Serum

Symptoms & Phenotypes for Immunoglobulin E Concentration, Serum

Clinical features from OMIM®:

147061 (Updated 05-Mar-2021)

Drugs & Therapeutics for Immunoglobulin E Concentration, Serum

Drugs for Immunoglobulin E Concentration, Serum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Nitric Oxide Approved Phase 4 10102-43-9 145068
Terbutaline Approved Phase 4 23031-25-6 5403
Norepinephrine Approved Phase 4 51-41-2 439260
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
Montelukast Approved Phase 4 158966-92-8 5281040
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Racepinephrine Approved Phase 4 329-65-7 838
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13 Lactams Phase 4
14 beta-Lactams Phase 4
15 Hormone Antagonists Phase 4
16 Hormones Phase 4
17 Neurotransmitter Agents Phase 4
18 Bronchodilator Agents Phase 4
Histamine Phosphate Phase 4 51-74-1 65513
20 Sympathomimetics Phase 4
21 Albuterol Phase 4
22 Tocolytic Agents Phase 4
23 Methacholine Chloride Phase 4
24 Adrenergic alpha-Agonists Phase 4
25 Mydriatics Phase 4
26 Vasoconstrictor Agents Phase 4
27 Leukotriene Antagonists Phase 4
28 Anti-Inflammatory Agents Phase 4
29 Adrenergic beta-Agonists Phase 4
30 glucocorticoids Phase 4
31 Adrenergic Agents Phase 4
32 Formoterol Fumarate Phase 4
33 Adrenergic Agonists Phase 4
34 Epinephryl borate Phase 4
35 Fluticasone-Salmeterol Drug Combination Phase 4
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
Etanercept Approved, Investigational Phase 3 185243-69-0
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
tannic acid Approved Phase 2, Phase 3 1401-55-4
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
Durvalumab Approved, Investigational Phase 3 1428935-60-7
Abatacept Approved Phase 3 332348-12-6 10237
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Tremelimumab Investigational Phase 3 745013-59-6
47 Analgesics, Non-Narcotic Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Analgesics Phase 3
50 Histamine Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
2 Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams Unknown status NCT01159379 Phase 4 ertapenem
3 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Unknown status NCT00673218 Phase 4 Placebo;Xolair
4 A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair) Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
5 A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
6 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20) Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
7 A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids Completed NCT00329381 Phase 4 Xolair;Xolair
8 Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
9 Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) Completed NCT00367016 Phase 4 Xolair (Omalizumab);Placebo
10 Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test Completed NCT00117611 Phase 4 Anti-IgE antibody omalizumab or placebo
11 Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils Completed NCT02023151 Phase 4 Omalizumab
12 Inner-City Anti-IgE Therapy for Asthma (ICAC-08) Completed NCT00377572 Phase 4
13 Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment. Completed NCT00454051 Phase 4 Omalizumab;placebo
14 A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations Completed NCT00624832 Phase 4 Xolair;Placebo
15 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
16 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria Completed NCT03111628 Phase 4 Omalizumab
17 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
18 A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
19 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
20 A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab) on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
21 Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial Completed NCT02063750 Phase 4
22 A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy Completed NCT00264849 Phase 4 Omalizumab
23 Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
24 The Effect of Xolair (Omalizumab) on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Completed NCT00657891 Phase 4 Omalizumab;Placebo
25 The Role of Nonspecific Immune Response of the Airway Mucosa in Children With Chronic Rhinosinusitis and Asthma Completed NCT03011632 Phase 4 Mometasone Nasal;placebo mometasone
26 The Effects on Airway Reactivity of the Use of Preoperative Montelukast Sodium Completed NCT02494466 Phase 4 montelukast sodium
27 Treatment With Omalizumab in Food Allergic Children (TOFAC) Recruiting NCT04037176 Phase 4 Omalizumab
28 Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana). Recruiting NCT03964051 Phase 4 Omalizumab Injection
29 A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma Recruiting NCT04195958 Phase 4 Omalizumab
30 A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema Active, not recruiting NCT02432547 Phase 4 Aflibercept
31 In Situ Analysis of Sputum-derived Cellular Targets After Xolair (Omalizumab). Terminated NCT02658877 Phase 4 Omalizumab;Placebo
32 Multicentric, Open-label, Randomized, Parallel--group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12- Month Period, in Patients With Severe IgE-mediated Asthma Inadequately Controlled With High Doses of Corticosteroids. Terminated NCT01912872 Phase 4 Omalizumab;Budesonide;Formoterol;Budesonide;Formoterol
33 Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab Terminated NCT00784485 Phase 4 Xolair injections
34 Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test Withdrawn NCT00603785 Phase 4 Placebo;Xolair
35 A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis Unknown status NCT02701205 Phase 3 placebo
36 The Effect of a Humanised Monoclonal Anti-IgE Antibody,Omalizumab, on Disease Control and Bronchial Mucosal Inflammation in Non-atpic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
37 Development,Effectiveness and Cost-effectiveness of a New Respiratory and Palliative Care Out-patient Breathlessness Support Service Unknown status NCT01165034 Phase 3
38 A Comparative Study of Efficacy and Safety of Genolar® and Xolar® in Treating Patients With Moderate to Severe Persistent Atopic Bronchial Asthma Inadequately Controlled With Stage 4 GINA (2017) Treatment Completed NCT04607629 Phase 3
39 A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00362349 Phase 3 IgNextGen 10%
40 A Multi-centre, Open-label, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of Ig NextGen 10% With Intragam P in Patients With Primary Immune Deficiency (PID) Completed NCT00405184 Phase 3 IntragamP;Ig NextGen 10%
41 A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy Completed NCT01202903 Phase 3 Omalizumab;Placebo
42 A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies Completed NCT03369704 Phase 3 Omalizumab;Placebo
43 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps Completed NCT03280550 Phase 3 Omalizumab;Placebo
44 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps Completed NCT03280537 Phase 3 Omalizumab;Placebo
45 Confirmatory Study to Examine Negative Predictive Value (NPV) and Safety of Skin Testing With PRE-PEN, a Minor Determinant MIxture (MDM) of Penicillin Antigens, and Amoxicillin Reagent Against an Oral Challenge With Amoxicillin Completed NCT01818336 Phase 3 Penicillin skin test kit
46 A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma Completed NCT01976208 Phase 2, Phase 3 Omalizumab;placebo
47 Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites Completed NCT00310492 Phase 3
48 An Open-Label Study of Ig NextGen 16% Administered by Subcutaneous Infusion in Patients With Primary Immunodeficiency (PID). Completed NCT00680446 Phase 3 Immunoglobulin G (Ig NextGen 16%)
49 Phase III Randomized Trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for Late Toxicity Reduction After Postoperative Radiotherapy in Ca Cervix. Completed NCT01279135 Phase 3
50 A Multi-centre, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Subcutaneous Infusions of Ig NextGen 16% in Patients With Primary Immunodeficiency (PID). Completed NCT00391131 Phase 3 IgNextGen 16%

Search NIH Clinical Center for Immunoglobulin E Concentration, Serum

Genetic Tests for Immunoglobulin E Concentration, Serum

Anatomical Context for Immunoglobulin E Concentration, Serum

MalaCards organs/tissues related to Immunoglobulin E Concentration, Serum:

Skin, Prostate, Lung, Liver, T Cells, Lymph Node, Colon

Publications for Immunoglobulin E Concentration, Serum

Articles related to Immunoglobulin E Concentration, Serum:

(show top 50) (show all 540)
# Title Authors PMID Year
An epigenome-wide association study of total serum immunoglobulin E concentration. 57
25707804 2015
Association between quantitative traits underlying asthma and the HLA-DRB1 locus in a family-based population sample. 57
11378822 2001
Major genes regulating total serum immunoglobulin E levels in families with asthma. 57
11023809 2000
Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families. 57
11093275 2000
Genetic control of serum IgE levels and asthma: linkage and linkage disequilibrium studies in an isolated population. 57
9328470 1997
Serum IgE concentration and other immune manifestations of treatment with gold salts are linked to the MHC and IL4 regions in the rat. 57
8808287 1996
Evidence for two unlinked loci regulating total serum IgE levels. 57
7668269 1995
Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. 57
7835897 1994
Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. 57
8178175 1994
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. 57
6770269 1980
Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy. 61
32562508 2021
Allergy-Related Symptoms Are Poorly Predicted by IgE and Skin Prick Testing in Early Life. 61
33550294 2021
Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE). 61
33418162 2021
Classification of patients with esophageal eosinophilia by patterns of sensitization revealed by a diagnostic assay for multiple allergen-specific IgEs. 61
33591429 2021
Variation in aggression rates and urinary cortisol levels indicates intergroup competition in wild bonobos. 61
33373622 2021
Influence of Antihistamines on Basophil Activation Test in Food Allergy to Milk and Egg. 61
33396589 2020
Selective impairment of auditory attention processing in idiopathic generalized epilepsies: Implications for their cognitive pathophysiology. 61
33284641 2020
Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene. 61
32450244 2020
A new optical interferometric-based in vitro detection system for the specific IgE detection in serum of the main peach allergen. 61
32992160 2020
Predictors of a positive oral food challenge to cow's milk in children sensitized to cow's milk. 61
32402626 2020
Epilepsy syndromes in Iran: A systematic review. 61
33222160 2020
Sex differences in characteristics of idiopathic generalized epilepsies. 61
33074451 2020
Study of the Anatomical Structure of the Nasopharyngeal Cavity and Distribution of the Air Flow Field. 61
32657986 2020
Baked Tolerance in Cow's Milk Allergy: Quite Frequent, Hard to Predict! 61
33053550 2020
Immunoglobulin E sialylation regulates allergic responses. 61
32632971 2020
Allergic symptoms and sensitisation in adolescents with cows' milk allergy and atopic eczema in infancy. 61
32567223 2020
Methodological and diagnostic relevance of IgEs to recombinant allergens Api m 1 and Ves v 5 determined by the multiplex test ImmunoCAP ISAC. 61
32511822 2020
How to diagnose and classify idiopathic (genetic) generalized epilepsies. 61
32782228 2020
Serological analysis of sensitization in allergic bronchopulmonary aspergillosis: a study on allergen components and interspecies relationships. 61
30943819 2020
Genetic/idiopathic generalized epilepsies: Not so good as that! 61
32423603 2020
Genotype-by-genotype epistasis for exploratory behaviour in D. simulans. 61
32517624 2020
[Determination of antispermal IgE antibodies in women with infertility and chronic inflammatory pelvic diseases.] 61
32762182 2020
Late-onset idiopathic (genetic) generalized epilepsies: Clinical and EEG findings. 61
32305275 2020
Exercise-induced allergic reactions on desensitization to wheat after rush oral immunotherapy. 61
31953936 2020
Tonic-clonic seizures in idiopathic generalized epilepsies: Prevalence, risk factors, and outcome. 61
32030724 2020
New candidates for regulated gene integrity revealed through precise mapping of integrative genetic elements. 61
32182341 2020
Epidemiological study of oral allergy syndrome in birch pollen dispersal-free regions. 61
31708436 2020
Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. 61
31980492 2020
Local fungus-specific Immunoglobulin E production in chronic rhinosinusitis with nasal polyps. 61
31904030 2020
Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids. 61
31483891 2020
Analysis of direct and indirect genetic effects in fighting sea anemones. 61
32210526 2020
Anaphylaxis to Beluga caviar. 61
30660175 2020
Indirect genetic effects on the relationships between production and feeding behaviour traits in growing Duroc pigs. 61
31571565 2020
An evolutionary switch from sibling rivalry to sibling cooperation, caused by a sustained loss of parental care. 61
31964847 2020
Antiviral activity of iridoid glycosides extracted from Fructus Gardeniae against influenza A virus by PACT-dependent suppression of viral RNA replication. 61
32024921 2020
Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. 61
31622668 2020
Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder. 61
32049976 2020
Associations between serum 25-hydroxyvitamin D levels and allergic sensitization in early childhood. 61
31601504 2020
Third-party verification of total and specific immunoglobulin E on analyzer Immulite® 2000XPi. 61
31606400 2020
Associations Between Metal Levels in Whole Blood and IgE Concentrations in Pregnant Women Based on Data From the Japan Environment and Children's Study. 61
30643099 2019

Variations for Immunoglobulin E Concentration, Serum

Expression for Immunoglobulin E Concentration, Serum

Search GEO for disease gene expression data for Immunoglobulin E Concentration, Serum.

Pathways for Immunoglobulin E Concentration, Serum

GO Terms for Immunoglobulin E Concentration, Serum

Sources for Immunoglobulin E Concentration, Serum

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....